Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Mehta, Rajeshwari ^a   Katta, Harshadadevi ^a   Alimirah, Fatouma ^a   Patel, Rutulkumar ^a   Murillo, Genoveva ^a   Peng, Xinjian ^a   Muzzio, Miguel ^a   Mehta, Rajendra G ^a  

^a IIT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEGUELIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; SURVIVIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BT 20 CELL STRAIN; BT 549 CELL STRAIN; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; FLUID INTAKE; FOOD INTAKE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MDA MB 231 CELL STRAIN; MDA MB 468 CELL STRAIN; MOLECULARLY TARGETED THERAPY; MOTOR PERFORMANCE; MOUSE; NONHUMAN; NUDE MOUSE; ORGAN WEIGHT; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TOXICITY TESTING; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; ROTENONE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUNDULEA SERICEA; MUS;

EID: 84878878719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065113     Document Type: Article

References (44)

1. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheng MC, et al. (2007) Use of immunohiostochemical markers can refineprognosis in triple negative breast cancer. BMC Cancer 7: 34-38.
2. Brouckaert O, Wildiers H, Floris G, Neven P, (2012) Update on triple-negative breast cancer: prognosis and management strategies Int J Womens Health. 4: 511-520.
3. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, et al. (2012) Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 136: 331-45.
4. Jin-Qiang C, Russo J, (2009) ERα-Negative and Triple Negative Breast Cancer: Molecular Features and Potential Therapeutic Approaches. Biochem Biophys Acta. 1796: 162-175.
5. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, et al. (2007) Differences in breast carcinoma characteritics in newly diagnosed African American and Caucasian patients: a single institution compilation compared with the national Cancer institutes surveillance epidemiology and end results database. Cancer 110: 876-884.
6. Griffiths CL, Olin JL, (2012) Triple negative breast cancer: a brief review of its characteristics and treatment options. J Pharm Pract. 25: 319-323.
7. André F, Zielinski CC, (2012) Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. (Suppl) 6: vi46-vi51.
8. Murillo G, Peng X, Torres KE, Mehta RG, (2009) Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev Res (Phila). 2: 942-950.
9. Bilici A, Arslan C, Altundag K, (2012) Promising therapeutic options in triple-negative breast cancer. J. Buon. 17: 209-222.
10. Gumuskaya B, Alper M, Hucumenoglu S, Altundag K, Uner A, et al. (2010) EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet Cytogenet. 203: 222-229.
11. Yarden Y, Sliwkowsji MX, (2001) Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127-137.
12. Nakajima H, Ishikawa Y, Furuya M, Sano T, Ohno Y, et al. (2012) Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer (e-pub ahead of publication).
13. Martínez-Carpio PA, Mur C, Rosel P, Navarro MA, (1999) Constitutive and regulated secretion of epidermal growth factor and transforming growth factor-beta1 in MDA-MB-231 breast cancer cell line in 11-day cultures. Cell Signal. 11: 753-757.
14. Chu ZH, Liang XH, Zhou XL, Huang RF, Zhan Q, et al. (2011) Effects of deguelin on proliferation and apoptosis of MCF-7 breast cancer cells by phosphatidylinositol 3-kinase/Akt signaling pathway. Zhong Xi Yi Jie He Xue Bao. 9: 533-538 (article in Chinese).
15. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, et al. (2012) McMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 18: 2269-2277.
16. Bilici A, Arslan C, Altundag K, (2012) Promising therapeutic options in triple-negative breast cancer. J BUON. 17: 209-222.
17. Turkson J, Jove R (2000) STAT proteins, novel molecular targets for cancer drug discovery. Oncogene 19, 6613-6626.
18. Yang J, Chatterjee-Kishore M, Staugaitis S M, Nguyen H, Schlessinger K, et al. (2005) Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65: 939-947.
19. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, et al. (2007) Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκB. Genes Dev. 21: 1396-1408.
20. Adida C, Berreri D, Peuchmaur M, Reyes Mugic M, et al. (1998) Anti apoptosis gene, survivin and prognosis of neuroblastoma. Lancet 351: 883-883.
21. Xu C, Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, et al. (2012) High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level. Breast Cancer. (e-pub ahead of publication).
22. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58: 5315-5320.
23. Waligórska-Stachura J, Jankowska A, Waśko R, Liebert W, Biczysko M, et al. (2012) Survivin-prognostic tumor biomarker in human neoplasms-review. Ginekol Pol. 83: 537-540.
24. Thamilselvan V, Menon M, Thamilselvan S, (2011) Anticancer efficacy of Deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway. Int J Cancer. 129: 2916-2927.
25. Davidson NE, Gelmann EP, Lippman ME, Dickson RB, (1987) Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines.Mol Endocrinol. 1: 216-223.
26. Ciardiello F, Kim N, McGeady ML, Liscia DS, Saeki T, et al. (1991) Expression of transforming growth factor α (TGFα) in breast cancer. Ann Oncol 2: 169-182.
27. Sizemore N, Cox AD, Barnard JA, Oldham SM, Reynolds ER, et al. (1999) Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides. Gastroenterology. 117: 567-576.
28. Eckert LB, Repasky GA, Ülkü AS, McFall A, Zhou H, et al. (2004) Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res. 64: 4585-4592.
29. Kozma SC, Bogaard ME, Buser K, (1987) The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res 15: 5963-5971.
30. Yuen H, Abramczyk O, Montgomery G, Chan K, Huang Y, et al. (2012) J. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells. Biosci Rep. 32: 413-422.
31. Dell'Eva R, Ambrosini C, Minghelli S, Noonan DM, Albini A, et al. (2007) The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. Carcinogenesis. 28: 404-413.
32. Nair AS, Shishodia S, Ahn KS, Kunnumakkara AB, Sethi G, et al. (2006) Deguelin, an Akt inhibitor, suppresses IkappaBalpha kinase activation leading to suppression of NF-kappaB-regulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion. J Immunol. 15 177): 5612-5622.
33. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, et al. (1992) Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol. 12: 5152-5158.
34. Zhang YW, Staal B, Essenburg C, Su Y, Kang L, et al. (2010) MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70: 6880-6890.
35. Matteucci E, Bendinelli P, Desiderio MA, (2009) Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis. 30: 937-945.
36. Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, et al. (2007) Epidermal Growth Factor Receptor Plays a Significant Role in Hepatocyte Growth Factor Mediated Biological Responses in Mammary Epithelial Cells. Cancer Biol Ther. 6: 561-570.
37. Takabatake D, Fujita T, Shien T, Kawasaki K, Taira N, et al. (2007) Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231). Int J Cancer 120(1): 181-188.
38. Aggarwal BB, Sung B, (2011) NF-κB in cancer: A Matter of Life and Death Cancer Discov. (6): 469-471.
39. Kang HW, Kim JM, Cha MY, Jung HC, Song IS, et al. (2012) Deguelin, an Akt inhibitor, down-regulates NF-κB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice. Dig Dis Sci. 57: 2873-82.
40. Huang WL, Yeh HH, Lin CC, Lai WW, Chang JY, et al. (2010) Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells. Mol Cancer 9: 309-315.
41. Caboni P, Sherer TB, Zhang N, Taylor G, Na HM, et al. (2004) Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chem Res Toxicol. 11: 1540-1548.
42. Yan Y, Wang Y, Tan Q, Lubet RA, You M, (2005) Efficacy of deguelin and silibinin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. Neoplasia 12: 1053-1057.
43. Mehta RG, Pezzuto JM (2002) Discovery of cancer preventive agents from naturalproducts: from plants to prevention. Curr Oncol Rep. 4: 478-86. Review.
44. Murillo G, Kosmeder JW 2nd, Pezzuto JM, Mehta RG, (2003) Deguelin suppresses the formation of carcinogen-induced aberrant crypt foci in the colon of CF-1 mice. Int J Cancer. 104: 7-11.